| Company Name | Novartis (Taiwan) Co., Ltd. |
|---|---|
| Protocol Number | CLMF237ATW01 |
| Title of Study | An observational, multi-center, prospective, open-label study to assess effectiveness, safety and tolerability of treatment with single pill combination of vildagliptin plus metformin(50mg/500mg, 50mg/850mg, 50mg/1000mg film-coated tablets)in type 2 diabetes mellitus patients in a real-world setting |
| Primary Objective | To assess the effectiveness of vildagliptin plus metformin SPC for the treatment in T2DM patients uncontrolled with metformin monotherapy as measured by change of HbA1c after treatment period of 24±6 week. |
| Number of Sites | 14 |
| Period of Study | From：January 29, 2015 to：March, 2017 |
| Number of Patients | 900人 |
| IRB Approval Date | December 31, 2014 |
| Publication Plan / Date | September, 2017 |
